Antisense oligonucleotides against human protein kinase C
First Claim
1. A method of inhibiting the expression of human protein kinase C in cells comprising contacting the cells with an antisense oligonucleotide having up to 50 nucleotide units, wherein said antisense oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 67, 69, 71, 73, 74, 75, 87, 89, 90, 91, 93, 106, 107, 109, 110, 111, 113, 115, 116, 117, 118, 119, 120 and 121, whereby said expression is inhibited.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. Oligonucleotides specifically hybridizable with a translation initiation site, 5'"'"'-untranslated region or 3'"'"'-untranslated region are provided. Oligonucleotides specifically hybridizable with a particular PKC isozyme or set of isozymes are also provided. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide targeted to PKC are disclosed.
-
Citations
16 Claims
-
1. A method of inhibiting the expression of human protein kinase C in cells comprising contacting the cells with an antisense oligonucleotide having up to 50 nucleotide units, wherein said antisense oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 67, 69, 71, 73, 74, 75, 87, 89, 90, 91, 93, 106, 107, 109, 110, 111, 113, 115, 116, 117, 118, 119, 120 and 121, whereby said expression is inhibited.
- View Dependent Claims (2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
4. The method of claim 4 wherein the modification is a 2'"'"'-O-alkyl or 2'"'"'-fluoro modification.
-
14. A method of inhibiting the expression of human protein kinase C-α
- comprising contacting cells with an antisense oligonucleotide having up to 50 nucleotide units and comprising SEQ ID NO;
2, whereby said expression is inhibited.
- comprising contacting cells with an antisense oligonucleotide having up to 50 nucleotide units and comprising SEQ ID NO;
-
15. A method of inhibiting the expression of human protein kinase C-α
- comprising contacting cells with an antisense oligonucleotide having up to 50 nucleotide units and comprising SEQ ID NO;
3, wherein said oligonucleotide is free of a 5'"'"'-dimethoxytrityl moiety, and whereby said expression is inhibited.
- comprising contacting cells with an antisense oligonucleotide having up to 50 nucleotide units and comprising SEQ ID NO;
-
16. A method of inhibiting the expression of human protein kinase C-α
- comprising contacting cells with an antisense oligonucleotide having up to 50 nucleotide units and comprising SEQ ID NO;
5, whereby said expression is inhibited.
- comprising contacting cells with an antisense oligonucleotide having up to 50 nucleotide units and comprising SEQ ID NO;
Specification